SLS Projected Dividend Yield
SELLAS Life Sciences Group Inc ( NASDAQ : SLS )SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. Co. is focused on the development of novel therapeutics for a range of cancer indications. Co.'s product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. 21 YEAR PERFORMANCE RESULTS |
SLS Dividend History Detail SLS Dividend News SLS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |